

Adam T Whaley-Connell

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1895224/publications.pdf>

Version: 2024-02-01

238
papers

10,645
citations

31949

53
h-index

40954

93
g-index

250
all docs

250
docs citations

250
times ranked

13465
citing authors

#	ARTICLE	IF	CITATIONS
1	Diabetic Kidney Disease: A Report From an ADA Consensus Conference. <i>Diabetes Care</i> , 2014, 37, 2864-2883.	4.3	781
2	Diabetic cardiomyopathy: a hyperglycaemia- and insulin-resistance-induced heart disease. <i>Diabetologia</i> , 2018, 61, 21-28.	2.9	501
3	Diabetic Kidney Disease: A Report From an ADA Consensus Conference. <i>American Journal of Kidney Diseases</i> , 2014, 64, 510-533.	2.1	439
4	Narrative Review: The Emerging Clinical Implications of the Role of Aldosterone in the Metabolic Syndrome and Resistant Hypertension. <i>Annals of Internal Medicine</i> , 2009, 150, 776.	2.0	309
5	Mitochondrial biogenesis in the metabolic syndrome and cardiovascular disease. <i>Journal of Molecular Medicine</i> , 2010, 88, 993-1001.	1.7	306
6	Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2007, 293, H2009-H2023.	1.5	248
7	Prevalence of CKD and Comorbid Illness in Elderly Patients in the United States: Results From the Kidney Early Evaluation Program (KEEP). <i>American Journal of Kidney Diseases</i> , 2010, 55, S23-S33.	2.1	230
8	Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes. <i>Cardiovascular Diabetology</i> , 2017, 16, 9.	2.7	205
9	Skeletal muscle insulin resistance: role of inflammatory cytokines and reactive oxygen species. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2008, 294, R673-R680.	0.9	204
10	CKD in the United States: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. <i>American Journal of Kidney Diseases</i> , 2008, 51, S13-S20.	2.1	162
11	Chronic kidney disease, prevalence of premature cardiovascular disease, and relationship to short-term mortality. <i>American Heart Journal</i> , 2008, 156, 277-283.	1.2	160
12	CKD and Cardiovascular Disease in Screened High-Risk Volunteer and General Populations: The Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. <i>American Journal of Kidney Diseases</i> , 2008, 51, S38-S45.	2.1	141
13	Redox Control of Renal Function and Hypertension. <i>Antioxidants and Redox Signaling</i> , 2008, 10, 2047-2089.	2.5	140
14	Aldosterone: Role in the Cardiometabolic Syndrome and Resistant Hypertension. <i>Progress in Cardiovascular Diseases</i> , 2010, 52, 401-409.	1.6	128
15	Low-Dose Mineralocorticoid Receptor Blockade Prevents Western Diet-Induced Arterial Stiffening in Female Mice. <i>Hypertension</i> , 2015, 66, 99-107.	1.3	125
16	Comparison of the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) Study Equations: Risk Factors for and Complications of CKD and Mortality in the Kidney Early Evaluation Program (KEEP). <i>American Journal of Kidney Diseases</i> , 2011, 57, S9-S16.	2.1	116
17	Uric Acid Promotes Left Ventricular Diastolic Dysfunction in Mice Fed a Western Diet. <i>Hypertension</i> , 2015, 65, 531-539.	1.3	114
18	The Role of Oxidative Stress in the Metabolic Syndrome. <i>Reviews in Cardiovascular Medicine</i> , 2011, 12, 21-29.	0.5	113

#	ARTICLE	IF	CITATIONS
19	Endothelial Mineralocorticoid Receptor Deletion Prevents Diet-Induced Cardiac Diastolic Dysfunction in Females. <i>Hypertension</i> , 2015, 66, 1159-1167.	1.3	111
20	Low-dose spironolactone reduces reactive oxygen species generation and improves insulin-stimulated glucose transport in skeletal muscle in the TG(mRen2)27 rat. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2008, 295, E110-E116.	1.8	102
21	Nebivolol Improves Diastolic Dysfunction and Myocardial Remodeling Through Reductions in Oxidative Stress in the Zucker Obese Rat. <i>Hypertension</i> , 2010, 55, 880-888.	1.3	102
22	Angiotensin II-induced non-alcoholic fatty liver disease is mediated by oxidative stress in transgenic TG(mRen2)27(Ren2) rats. <i>Journal of Hepatology</i> , 2008, 49, 417-428.	1.8	101
23	The Role of Overweight and Obesity in the Cardiorenal Syndrome. <i>CardioRenal Medicine</i> , 2011, 1, 5-12.	0.7	101
24	NADPH Oxidase Contributes to Vascular Inflammation, Insulin Resistance, and Remodeling in the Transgenic (mRen2) Rat. <i>Hypertension</i> , 2007, 50, 384-391.	1.3	100
25	Autophagy as an emerging target in cardiorenal metabolic disease: From pathophysiology to management. , 2018, 191, 1-22.		100
26	Oxidative stress and glomerular filtration barrier injury: role of the renin-angiotensin system in the Ren2 transgenic rat. <i>American Journal of Physiology - Renal Physiology</i> , 2006, 291, F1308-F1314.	1.3	99
27	Mineralocorticoid Receptor Blockade Attenuates Chronic Overexpression of the Renin-Angiotensin-Aldosterone System Stimulation of Reduced Nicotinamide Adenine Dinucleotide Phosphate Oxidase and Cardiac Remodeling. <i>Endocrinology</i> , 2007, 148, 3773-3780.	1.4	96
28	Prevalence and Associations of Anemia of CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. <i>American Journal of Kidney Diseases</i> , 2008, 51, S46-S55.	2.1	95
29	Diabetes Mellitus and CKD Awareness: The Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES). <i>American Journal of Kidney Diseases</i> , 2009, 53, S11-S21.	2.1	95
30	Obesity and kidney disease: from population to basic science and the search for new therapeutic targets. <i>Kidney International</i> , 2017, 92, 313-323.	2.6	93
31	Attenuation of NADPH Oxidase Activation and Glomerular Filtration Barrier Remodeling With Statin Treatment. <i>Hypertension</i> , 2008, 51, 474-480.	1.3	90
32	Direct Renin Inhibition Improves Systemic Insulin Resistance and Skeletal Muscle Glucose Transport in a Transgenic Rodent Model of Tissue Renin Overexpression. <i>Endocrinology</i> , 2009, 150, 2561-2568.	1.4	87
33	Contribution of oxidative stress to pulmonary arterial hypertension. <i>World Journal of Cardiology</i> , 2010, 2, 316.	0.5	87
34	Dipeptidylpeptidase Inhibition Is Associated with Improvement in Blood Pressure and Diastolic Function in Insulin-Resistant Male Zucker Obese Rats. <i>Endocrinology</i> , 2013, 154, 2501-2513.	1.4	86
35	Angiotensin II-mediated oxidative stress promotes myocardial tissue remodeling in the transgenic (mRen2) 27 Ren2 rat. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2007, 293, E355-E363.	1.8	84
36	Arterial Stiffness in Hypertension: an Update. <i>Current Hypertension Reports</i> , 2018, 20, 72.	1.5	77

#	ARTICLE	IF	CITATIONS
37	Renal Redox Stress and Remodeling in Metabolic Syndrome, Type 2 Diabetes mellitus, and Diabetic Nephropathy: Paying Homage to the Podocyte. <i>American Journal of Nephrology</i> , 2005, 25, 553-569.	1.4	74
38	The Synergistic Relationship Between Estimated GFR and Microalbuminuria in Predicting Long-term Progression to ESRD or Death in Patients With Diabetes: Results From the Kidney Early Evaluation Program (KEEP). <i>American Journal of Kidney Diseases</i> , 2013, 61, S12-S23.	2.1	72
39	Oxidative stress contributes to pulmonary hypertension in the transgenic (mRen2)27 rat. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2008, 294, H2659-H2668.	1.5	69
40	Renin Inhibition Attenuates Insulin Resistance, Oxidative Stress, and Pancreatic Remodeling in the Transgenic Ren2 Rat. <i>Endocrinology</i> , 2008, 149, 5643-5653.	1.4	69
41	The Cardiometabolic Syndrome as a Cardiovascular Risk Factor. <i>American Journal of the Medical Sciences</i> , 2005, 330, 311-318.	0.4	68
42	Educational programs improve the preparation for dialysis and survival of patients with chronic kidney disease. <i>Kidney International</i> , 2014, 85, 686-692.	2.6	68
43	Rosuvastatin, a 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor, Decreases Cardiac Oxidative Stress and Remodeling in Ren2 Transgenic Rats. <i>Endocrinology</i> , 2007, 148, 2181-2188.	1.4	67
44	Differential regulation of angiotensin-(1-12) in plasma and cardiac tissue in response to bilateral nephrectomy. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2009, 296, H1184-H1192.	1.5	66
45	Insulin Resistance in Kidney Disease: Is There a Distinct Role Separate from That of Diabetes or Obesity. <i>CardioRenal Medicine</i> , 2018, 8, 41-49.	0.7	65
46	Mineralocorticoid receptor blockade improves diastolic function independent of blood pressure reduction in a transgenic model of RAAS overexpression. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2011, 300, H1484-H1491.	1.5	62
47	DPP4 inhibition attenuates filtration barrier injury and oxidant stress in the Zucker obese rat. <i>Obesity</i> , 2014, 22, 2172-2179.	1.5	62
48	Albumin Activation of NAD(P)H Oxidase Activity Is Mediated via Rac1 in Proximal Tubule Cells. <i>American Journal of Nephrology</i> , 2007, 27, 15-23.	1.4	61
49	Attenuation of Endocrine-Exocrine Pancreatic Communication in Type 2 Diabetes: Pancreatic Extracellular Matrix Ultrastructural Abnormalities. <i>Journal of the Cardiometabolic Syndrome</i> , 2008, 3, 234-243.	1.7	61
50	Trends in Mineral Metabolism: Kidney Early Evaluation Program (KEEP) and the National Health and Nutrition Examination Survey (NHANES) 1999-2004. <i>American Journal of Kidney Diseases</i> , 2008, 51, S56-S68.	2.1	60
51	The Key Role of Insulin Resistance in the Cardiometabolic Syndrome. <i>American Journal of the Medical Sciences</i> , 2005, 330, 290-294.	0.4	58
52	Dipeptidyl peptidase-4 (DPP-4) inhibition with linagliptin reduces western diet-induced myocardial TRAF3IP2 expression, inflammation and fibrosis in female mice. <i>Cardiovascular Diabetology</i> , 2017, 16, 61.	2.7	58
53	Hypertension and the Cardiometabolic Syndrome. <i>Journal of Clinical Hypertension</i> , 2005, 7, 471-476.	1.0	56
54	Oxidative Stress-Mediated Mitochondrial Dysfunction Contributes to Angiotensin II-Induced Nonalcoholic Fatty Liver Disease in Transgenic Ren2 Rats. <i>American Journal of Pathology</i> , 2009, 174, 1329-1337.	1.9	56

#	ARTICLE	IF	CITATIONS
55	Nebivolol Reduces Proteinuria and Renal NADPH Oxidase-Generated Reactive Oxygen Species in the Transgenic Ren2 Rat. <i>American Journal of Nephrology</i> , 2009, 30, 354-360.	1.4	55
56	No independent association of serum phosphorus with risk for death or progression to end-stage renal disease in a large screen for chronic kidney disease. <i>Kidney International</i> , 2013, 84, 989-997.	2.6	54
57	Awareness of Kidney Disease and Relationship to End-stage Renal Disease and Mortality. <i>American Journal of Medicine</i> , 2012, 125, 661-669.	0.6	53
58	Inhibition of nitric oxide synthase evokes central sympathoexcitation in healthy humans. <i>Journal of Physiology</i> , 2009, 587, 4977-4986.	1.3	51
59	Association Between Lack of Health Insurance and Risk of Death and ESRD: Results From the Kidney Early Evaluation Program (KEEP). <i>American Journal of Kidney Diseases</i> , 2013, 61, S24-S32.	2.1	51
60	Obesity and Insulin Resistance in Resistant Hypertension: Implications for the Kidney. <i>Advances in Chronic Kidney Disease</i> , 2015, 22, 211-217.	0.6	51
61	Effect of renin inhibition and AT ₁ R blockade on myocardial remodeling in the transgenic Ren2 rat. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2008, 295, E103-E109.	1.8	50
62	Nebivolol improves diastolic dysfunction and myocardial remodeling through reductions in oxidative stress in the transgenic (mRen2) rat. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2012, 302, H2341-H2351.	1.5	50
63	Oxidative Stress in the Cardiorenal Metabolic Syndrome. <i>Current Hypertension Reports</i> , 2012, 14, 360-365.	1.5	50
64	Uric acid promotes vascular stiffness, maladaptive inflammatory responses and proteinuria in western diet fed mice. <i>Metabolism: Clinical and Experimental</i> , 2017, 74, 32-40.	1.5	49
65	Cytokine Abnormalities in the Etiology of the Cardiometabolic Syndrome. <i>Current Hypertension Reports</i> , 2010, 12, 93-98.	1.5	48
66	Hypertension in Cardiovascular and Kidney Disease. <i>CardioRenal Medicine</i> , 2011, 1, 183-192.	0.7	48
67	DPP-4 Inhibitors as Therapeutic Modulators of Immune Cell Function and Associated Cardiovascular and Renal Insulin Resistance in Obesity and Diabetes. <i>CardioRenal Medicine</i> , 2013, 3, 48-56.	0.7	48
68	BP and Renal Outcomes in Diabetic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 2159-2169.	2.2	48
69	Diabetes Mellitus in CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition and Examination Survey (NHANES) 1999-2004. <i>American Journal of Kidney Diseases</i> , 2008, 51, S21-S29.	2.1	47
70	Exercise and the metabolic syndrome with weight regain. <i>Journal of Applied Physiology</i> , 2010, 109, 3-10.	1.2	47
71	Possible Mechanisms of Local Tissue Renin-Angiotensin System Activation in the Cardiorenal Metabolic Syndrome and Type 2 Diabetes Mellitus. <i>CardioRenal Medicine</i> , 2011, 1, 193-210.	0.7	46
72	Obesity-Related Alterations in Cardiac Lipid Profile and Nondipping Blood Pressure Pattern during Transition to Diastolic Dysfunction in Male db/db Mice. <i>Endocrinology</i> , 2013, 154, 159-171.	1.4	46

#	ARTICLE	IF	CITATIONS
73	Prevention of Obesity-Induced Renal Injury in Male Mice by DPP4 Inhibition. <i>Endocrinology</i> , 2014, 155, 2266-2276.	1.4	46
74	Insulin Resistance, Oxidative Stress, and Podocyte Injury: Role of Rosuvastatin Modulation of Filtration Barrier Injury. <i>American Journal of Nephrology</i> , 2008, 28, 67-75.	1.4	45
75	Mineralocorticoid receptor antagonism attenuates glomerular filtration barrier remodeling in the transgenic Ren2 rat. <i>American Journal of Physiology - Renal Physiology</i> , 2009, 296, F1013-F1022.	1.3	45
76	Fructose and Uric Acid: Is There a Role in Endothelial Function?. <i>Current Hypertension Reports</i> , 2014, 16, 434.	1.5	45
77	Cardiometabolic Syndrome and Chronic Kidney Disease: What Is the Link?. <i>Journal of the Cardiometabolic Syndrome</i> , 2006, 1, 58-65.	1.7	43
78	Hyponatremia, Arginine Vasopressin Dysregulation, and Vasopressin Receptor Antagonism. <i>American Journal of Nephrology</i> , 2006, 26, 579-589.	1.4	42
79	CKD Awareness in the United States: The Kidney Early Evaluation Program (KEEP). <i>American Journal of Kidney Diseases</i> , 2008, 52, 382-383.	2.1	42
80	Mineralocorticoid Receptor Antagonism Attenuates Vascular Apoptosis and Injury via Rescuing Protein Kinase B Activation. <i>Hypertension</i> , 2009, 53, 158-165.	1.3	42
81	Association of Race and Body Mass Index With ESRD and Mortality in CKD Stages 3-4: Results From the Kidney Early Evaluation Program (KEEP). <i>American Journal of Kidney Diseases</i> , 2013, 61, 404-412.	2.1	42
82	Hypertension and Insulin Resistance. <i>Hypertension</i> , 2009, 54, 462-464.	1.3	41
83	Diet-Induced Obesity Promotes Kidney Endothelial Stiffening and Fibrosis Dependent on the Endothelial Mineralocorticoid Receptor. <i>Hypertension</i> , 2019, 73, 849-858.	1.3	41
84	Cardiovascular Disease in Chronic Kidney Disease: Data from the Kidney Early Evaluation Program (KEEP). <i>Current Diabetes Reports</i> , 2011, 11, 47-55.	1.7	40
85	Nebivolol Attenuates Redox-Sensitive Glomerular and Tubular Mediated Proteinuria in Obese Rats. <i>Endocrinology</i> , 2011, 152, 659-668.	1.4	40
86	Angiotensin II Activation of mTOR Results in Tubulointerstitial Fibrosis through Loss of N-Cadherin. <i>American Journal of Nephrology</i> , 2011, 34, 115-125.	1.4	40
87	Adaptive mechanisms to compensate for overnutrition-induced cardiovascular abnormalities. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2011, 301, R885-R895.	0.9	40
88	Epithelial sodium channels in endothelial cells mediate diet-induced endothelium stiffness and impaired vascular relaxation in obese female mice. <i>Metabolism: Clinical and Experimental</i> , 2019, 99, 57-66.	1.5	40
89	The Impact of Overnutrition on Insulin Metabolic Signaling in the Heart and the Kidney. <i>CardioRenal Medicine</i> , 2011, 1, 102-112.	0.7	39
90	Access to Health Care Among Adults Evaluated for CKD: Findings From the Kidney Early Evaluation Program (KEEP). <i>American Journal of Kidney Diseases</i> , 2012, 59, S5-S15.	2.1	39

#	ARTICLE	IF	CITATIONS
91	Gestational Diabetes Mellitus Alone in the Absence of Subsequent Diabetes Is Associated With Microalbuminuria. <i>Diabetes Care</i> , 2010, 33, 2586-2591.	4.3	38
92	Early Treatment With Olmesartan Prevents Juxtamedullary Glomerular Podocyte Injury and the Onset of Microalbuminuria in Type 2 Diabetic Rats. <i>American Journal of Hypertension</i> , 2012, 25, 604-611.	1.0	38
93	Comparative effect of direct renin inhibition and AT ₁ R blockade on glomerular filtration barrier injury in the transgenic Ren2 rat. <i>American Journal of Physiology - Renal Physiology</i> , 2010, 298, F655-F661.	1.3	37
94	Amiloride Improves Endothelial Function and Reduces Vascular Stiffness in Female Mice Fed a Western Diet. <i>Frontiers in Physiology</i> , 2017, 8, 456.	1.3	37
95	Enhanced endothelium epithelial sodium channel signaling prompts left ventricular diastolic dysfunction in obese female mice. <i>Metabolism: Clinical and Experimental</i> , 2018, 78, 69-79.	1.5	35
96	Deficiency of IL12p40 (Interleukin 12 p40) Promotes Ang II (Angiotensin II)-Induced Abdominal Aortic Aneurysm. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 212-223.	1.1	34
97	Diabetic Kidney Disease and the Cardiorenal Syndrome. <i>Endocrinology and Metabolism Clinics of North America</i> , 2013, 42, 789-808.	1.2	33
98	Risk Factors for ESRD in Individuals With Preserved Estimated GFR With and Without Albuminuria: Results From the Kidney Early Evaluation Program (KEEP). <i>American Journal of Kidney Diseases</i> , 2013, 61, S4-S11.	2.1	33
99	The Emerging Role of Biomarkers in Diabetic and Hypertensive Chronic Kidney Disease. <i>Current Diabetes Reports</i> , 2010, 10, 37-42.	1.7	32
100	Indices of Obesity and Cardiometabolic Risk. <i>Hypertension</i> , 2011, 58, 991-993.	1.3	32
101	Basic science. <i>Journal of the American Society of Hypertension</i> , 2014, 8, 604-606.	2.3	32
102	Renin-angiotensin-aldosterone system-mediated redox effects in chronic kidney disease. <i>Translational Research</i> , 2009, 153, 102-113.	2.2	31
103	Comparison of CKD Awareness in a Screening Population Using the Modification of Diet in Renal Disease (MDRD) Study and CKD Epidemiology Collaboration (CKD-EPI) Equations. <i>American Journal of Kidney Diseases</i> , 2011, 57, S17-S23.	2.1	31
104	Mineralocorticoid Receptor-Dependent Proximal Tubule Injury Is Mediated by a Redox-Sensitive mTOR/S6K1 Pathway. <i>American Journal of Nephrology</i> , 2012, 35, 90-100.	1.4	31
105	Dysglycemia Predicts Cardiovascular and Kidney Disease in the Kidney Early Evaluation Program. <i>Journal of Clinical Hypertension</i> , 2010, 12, 51-58.	1.0	29
106	Use of Metformin in Patients with Kidney and Cardiovascular Diseases. <i>CardioRenal Medicine</i> , 2011, 1, 87-95.	0.7	29
107	Associations Between Access to Care and Awareness of CKD. <i>American Journal of Kidney Diseases</i> , 2012, 59, S16-S23.	2.1	29
108	Angiotensin II Stimulation of DPP4 Activity Regulates Megalin in the Proximal Tubules. <i>International Journal of Molecular Sciences</i> , 2016, 17, 780.	1.8	29

#	ARTICLE	IF	CITATIONS
109	Proximal tubule microvilli remodeling and albuminuria in the Ren2 transgenic rat. <i>American Journal of Physiology - Renal Physiology</i> , 2007, 292, F861-F867.	1.3	28
110	Comparison of the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) Study Equations: Prevalence of and Risk Factors for Diabetes Mellitus in CKD in the Kidney Early Evaluation Program (KEEP). <i>American Journal of Kidney Diseases</i> , 2011, 57, S24-S31.	2.1	28
111	Sex differences in baroreflex sensitivity, heart rate variability, and end organ damage in the TGR(mRen2)27 rat. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2011, 301, H1540-H1550.	1.5	28
112	Physician Utilization, Risk-Factor Control, and CKD Progression Among Participants in the Kidney Early Evaluation Program (KEEP). <i>American Journal of Kidney Diseases</i> , 2012, 59, S24-S33.	2.1	27
113	Rosuvastatin ameliorates the development of pulmonary arterial hypertension in the transgenic (mRen2)27 rat. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2009, 297, H1128-H1139.	1.5	26
114	Hypertension Management in Diabetic Kidney Disease. <i>Diabetes Spectrum</i> , 2015, 28, 175-180.	0.4	26
115	Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: results from the AMADEO study. <i>Vascular Health and Risk Management</i> , 2009, 5, 129-40.	1.0	26
116	Sustainable Community-Based CKD Screening Methods Employed by the National Kidney Foundation's Kidney Early Evaluation Program (KEEP). <i>American Journal of Kidney Diseases</i> , 2011, 57, S4-S8.	2.1	25
117	Obesity and Insulin Resistance As Risk Factors for Chronic Kidney Disease. <i>Journal of the Cardiometabolic Syndrome</i> , 2006, 1, 209-216.	1.7	24
118	Chronic kidney disease and cardiovascular risk. <i>Journal of the American Society of Hypertension</i> , 2007, 1, 178-184.	2.3	24
119	Nebivolol in Obese and Non-Obese Hypertensive Patients. <i>Journal of Clinical Hypertension</i> , 2009, 11, 309-315.	1.0	24
120	Obesity is associated with increased parathyroid hormone levels independent of glomerular filtration rate in chronic kidney disease. <i>Metabolism: Clinical and Experimental</i> , 2010, 59, 385-389.	1.5	24
121	To <sc>RAS</sc> or Not to <sc>RAS</sc>? The Evidence for and Cautions with Renin-Angiotensin System Inhibition in Patients with Diabetic Kidney Disease. <i>Pharmacotherapy</i> , 2013, 33, 496-514.	1.2	23
122	Hypertension Management in Type 2 Diabetes Mellitus: Recommendations of the Joint National Committee VII. <i>Endocrinology and Metabolism Clinics of North America</i> , 2005, 34, 63-75.	1.2	22
123	Sexual Dimorphism in Obesity-Associated Endothelial ENaC Activity and Stiffening in Mice. <i>Endocrinology</i> , 2019, 160, 2918-2928.	1.4	22
124	Nebivolol improves insulin sensitivity in the TGR(Ren2)27 rat. <i>Metabolism: Clinical and Experimental</i> , 2011, 60, 1757-1766.	1.5	21
125	Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: results from the AMADEO study. <i>Vascular Health and Risk Management</i> , 2008, , 129.	1.0	20
126	Renin Inhibition and AT1R blockade improve metabolic signaling, oxidant stress and myocardial tissue remodeling. <i>Metabolism: Clinical and Experimental</i> , 2013, 62, 861-872.	1.5	20

#	ARTICLE	IF	CITATIONS
127	Review: Renin-angiotensin-aldosterone system intervention in the cardiometabolic syndrome and cardio-renal protection. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2007, 1, 27-35.	1.0	19
128	Antihypertensive medications and their effects on lipid metabolism. <i>Current Diabetes Reports</i> , 2008, 8, 214-220.	1.7	19
129	Racial Differences in Kidney Function Among Individuals With Obesity and Metabolic Syndrome: Results From the Kidney Early Evaluation Program (KEEP). <i>American Journal of Kidney Diseases</i> , 2010, 55, S4-S14.	2.1	19
130	Resistant Hypertension in the High-Risk Metabolic Patient. <i>Current Diabetes Reports</i> , 2011, 11, 41-46.	1.7	19
131	Resistance to insulin and kidney disease in the cardiorenal metabolic syndrome; role for angiotensin II. <i>Molecular and Cellular Endocrinology</i> , 2013, 378, 53-58.	1.6	19
132	Low Aerobic Capacity and High-Fat Diet Contribute to Oxidative Stress and IRS-1 Degradation in the Kidney. <i>American Journal of Nephrology</i> , 2009, 30, 112-119.	1.4	18
133	Diabetic Cardiovascular Disease Predicts Chronic Kidney Disease Awareness in the Kidney Early Evaluation Program. <i>CardioRenal Medicine</i> , 2011, 1, 45-52.	0.7	17
134	Comparative analysis of telmisartan and olmesartan on cardiac function in the transgenic (mRen2) ²⁷ rat. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2011, 300, H181-H190.	1.5	17
135	Insights into the emerging cardiometabolic prevention and management of diabetes mellitus. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 2209-2221.	0.9	16
136	Overnutrition and the Cardiorenal Syndrome: Use of a Rodent Model to Examine Mechanisms. <i>CardioRenal Medicine</i> , 2011, 1, 23-30.	0.7	16
137	Hypoglycemia: A Possible Link between Insulin Resistance, Metabolic Dyslipidemia, and Heart and Kidney Disease (the Cardiorenal Syndrome). <i>CardioRenal Medicine</i> , 2011, 1, 67-74.	0.7	16
138	Regulation of Overnutrition-Induced Cardiac Inflammatory Mechanisms by nebivolol. <i>CardioRenal Medicine</i> , 2012, 2, 225-233.	0.7	16
139	Diabetes and Hypertension: Clinical Update. <i>American Journal of Hypertension</i> , 2018, 31, 515-521.	1.0	16
140	Combination of direct renin inhibition with angiotensin type 1 receptor blockade improves aldosterone but does not improve kidney injury in the transgenic Ren2 rat. <i>Regulatory Peptides</i> , 2012, 176, 36-44.	1.9	15
141	Advances in CKD Detection and Determination of Prognosis: Executive Summary of the National Kidney Foundation's "Kidney Early Evaluation Program (KEEP) 2012 Annual Data Report. <i>American Journal of Kidney Diseases</i> , 2013, 61, S1-S3.	2.1	15
142	Liquid meal composition, postprandial satiety hormones, and perceived appetite and satiety in obese women during acute caloric restriction. <i>European Journal of Endocrinology</i> , 2013, 168, 593-600.	1.9	15
143	Nebivolol Attenuates Maladaptive Proximal Tubule Remodeling in Transgenic Rats. <i>American Journal of Nephrology</i> , 2010, 31, 262-272.	1.4	14
144	Mineralocorticoid and Apparent Mineralocorticoid Syndromes of Secondary Hypertension. <i>Advances in Chronic Kidney Disease</i> , 2015, 22, 185-195.	0.6	14

#	ARTICLE	IF	CITATIONS
145	Hypertension in people with diabetes and the metabolic syndrome: Pathophysiologic insights and therapeutic update. <i>Current Diabetes Reports</i> , 2007, 7, 208-217.	1.7	13
146	Salt loading exacerbates diastolic dysfunction and cardiac remodeling in young female Ren2 rats. <i>Metabolism: Clinical and Experimental</i> , 2013, 62, 1761-1771.	1.5	13
147	Endothelial sodium channel activation promotes cardiac stiffness and diastolic dysfunction in Western diet fed female mice. <i>Metabolism: Clinical and Experimental</i> , 2020, 109, 154223.	1.5	13
148	Western diet induces renal artery endothelial stiffening that is dependent on the epithelial Na ⁺ channel. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 318, F1220-F1228.	1.3	13
149	Aldosterone and Hypertension in the Cardiometabolic Syndrome. <i>Journal of Clinical Hypertension</i> , 2008, 10, 94-96.	1.0	12
150	Aldosterone and Risk for Insulin Resistance. <i>Hypertension</i> , 2011, 58, 998-1000.	1.3	12
151	The Association between Parathyroid Hormone Levels and the Cardiorenal Metabolic Syndrome in Non-Diabetic Chronic Kidney Disease. <i>CardioRenal Medicine</i> , 2011, 1, 123-130.	0.7	11
152	Novel role for the incretins in blood pressure regulation. <i>Current Opinion in Nephrology and Hypertension</i> , 2012, 21, 463-468.	1.0	11
153	Therapy of obese patients with cardiovascular disease. <i>Current Opinion in Pharmacology</i> , 2013, 13, 200-204.	1.7	11
154	The Effects of Resistance Training on Metabolic Health With Weight Regain. <i>Journal of Clinical Hypertension</i> , 2010, 12, 64-72.	1.0	10
155	The Association of Parathyroid Hormone with ESRD and Pre-ESRD Mortality in the Kidney Early Evaluation Program. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 4414-4421.	1.8	10
156	National Kidney Foundation's Kidney Early Evaluation Program (KEEP) Annual Data Report 2011: Executive Summary. <i>American Journal of Kidney Diseases</i> , 2012, 59, S1-S4.	2.1	10
157	Salt Loading Promotes Kidney Injury via Fibrosis in Young Female Ren2 Rats. <i>CardioRenal Medicine</i> , 2014, 4, 43-52.	0.7	10
158	Two-Dimensional Zymography Differentiates Gelatinase Isoforms in Stimulated Microglial Cells and in Brain Tissues of Acute Brain Injuries. <i>PLoS ONE</i> , 2015, 10, e0123852.	1.1	10
159	Rates of continuous ambulatory peritoneal dialysis-associated peritonitis at the University of Missouri. <i>Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis</i> , 2005, 21, 72-5.	0.1	10
160	Central Pressure and Biomarker Responses to Renin Inhibition with Hydrochlorothiazide and Ramipril in Obese Hypertensives: The ATTAIN Study. <i>CardioRenal Medicine</i> , 2011, 1, 53-66.	0.7	9
161	Dysglycemia but not lipids is associated with abnormal urinary albumin excretion in diabetic kidney disease: a report from the Kidney Early Evaluation Program (KEEP). <i>BMC Nephrology</i> , 2012, 13, 104.	0.8	9
162	Obesity and Heart Failure as a Mediator of the Cerebrorenal Interaction. <i>Contributions To Nephrology</i> , 2013, 179, 15-23.	1.1	9

#	ARTICLE	IF	CITATIONS
163	The Association between Parathyroid Hormone Levels and Hemoglobin in Diabetic and Nondiabetic Participants in the National Kidney Foundation's Kidney Early Evaluation Program. <i>CardioRenal Medicine</i> , 2013, 3, 120-127.	0.7	9
164	Recommendations for Special Populations. , 2004, 14, 368-381.		8
165	Obesity, Insulin Resistance, and Nocturnal Systolic Blood Pressure. <i>Hypertension</i> , 2008, 51, 620-621.	1.3	8
166	National Kidney Foundation's Kidney Early Evaluation Program (KEEP) Annual Data Report 2010: Executive Summary. <i>American Journal of Kidney Diseases</i> , 2011, 57, S1-S3.	2.1	8
167	Association of Physician Care With Mortality in Kidney Early Evaluation Program (KEEP) Participants. <i>American Journal of Kidney Diseases</i> , 2012, 59, S34-S39.	2.1	8
168	Type 2 Diabetes in Older People; The Importance of Blood Pressure Control. <i>Current Cardiovascular Risk Reports</i> , 2013, 7, 233-237.	0.8	8
169	The importance of early identification of chronic kidney disease. <i>Missouri Medicine</i> , 2011, 108, 25-8.	0.3	8
170	Role of angiotensin II in diabetic cardiovascular and renal disease. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2006, 13, 135-140.	0.6	7
171	A Decade After the KDOQI CKD Guidelines: Impact on the National Kidney Foundation's Kidney Early Evaluation Program (KEEP). <i>American Journal of Kidney Diseases</i> , 2012, 60, 692-693.	2.1	7
172	Implications for Glucose Measures in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. <i>Diabetes</i> , 2014, 63, 45-47.	0.3	7
173	DPP4 inhibition mitigates ANG II-mediated kidney immune activation and injury in male mice. <i>American Journal of Physiology - Renal Physiology</i> , 2021, 320, F505-F517.	1.3	7
174	Cystamine reduces vascular stiffness in Western diet-fed female mice. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2022, 322, H167-H180.	1.5	7
175	Hypertension in the High-Cardiovascular-Risk Populations. <i>International Journal of Hypertension</i> , 2011, 2011, 1-3.	0.5	6
176	Insulin Resistance and the Autonomic Nervous System. , 2012, , 307-312.		6
177	Treatment of Diabetic Kidney Disease With Hypertension Control and Renin Angiotensin System Inhibition. <i>Advances in Chronic Kidney Disease</i> , 2018, 25, 158-165.	0.6	6
178	Utility of obesity and metabolic dyslipidemia (a non-insulin based determinate of the metabolic) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 2019, 21, 1071-1074.	1.0	6
179	Targeting mineralocorticoid receptors in diet-induced hepatic steatosis and insulin resistance. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2022, 322, R253-R262.	0.9	6
180	Inhibition of sphingomyelinase attenuates diet-induced increases in aortic stiffness. <i>Journal of Molecular and Cellular Cardiology</i> , 2022, 167, 32-39.	0.9	6

#	ARTICLE	IF	CITATIONS
181	Angiotensin type 1 receptor resistance to blockade in the opossum proximal tubule cell due to variations in the binding pocket. <i>American Journal of Physiology - Renal Physiology</i> , 2013, 304, F1105-F1113.	1.3	5
182	Blood Pressure-Related Outcomes in a Diabetic Population. <i>Hypertension</i> , 2016, 68, 34-35.	1.3	5
183	Diabetic Hypertension. <i>Heart Failure Clinics</i> , 2006, 2, 25-36.	1.0	4
184	Tonsillectomy for the treatment of tonsillitis-induced immunoglobulin A nephropathy. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 2010, 31, 485-488.	0.6	4
185	Mineralocorticoid Receptor in Myeloid Cells Mediates Angiotensin II-Induced Vascular Dysfunction in Female Mice. <i>Frontiers in Physiology</i> , 2021, 12, 588358.	1.3	4
186	Hypertension and Cardiovascular Disease. , 2006, , 499-513.		4
187	Chronic Kidney Disease and the Cardiometabolic Syndrome. <i>Journal of Clinical Hypertension</i> , 2006, 8, 546-548.	1.0	3
188	Review: Therapy for the altered mineral metabolism of chronic kidney disease: implications for vascular calcification. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2007, 1, 107-112.	1.0	3
189	Chronic kidney disease as a cardiovascular risk state and considerations for the use of statins. <i>Journal of Clinical Lipidology</i> , 2008, 2, 318-327.	0.6	3
190	Effect of Ethnicity on the Progression of Diabetic Kidney Disease Independent of Glycemic Control. <i>American Journal of Nephrology</i> , 2009, 30, 261-267.	1.4	3
191	Is there a future for direct renin inhibitors?. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 653-661.	1.9	3
192	A Case for Early Screening for Diabetic Kidney Disease. <i>CardioRenal Medicine</i> , 2011, 1, 235-242.	0.7	3
193	Over-nutrition contributes to tubulointerstitial fibrosis by targeting nutrient-sensing kinases. <i>Cell Cycle</i> , 2012, 11, 831-832.	1.3	3
194	The Use and Interpretation of Troponin in <sc>ESRD</sc> Patients. <i>Seminars in Dialysis</i> , 2014, 27, 545-547.	0.7	3
195	Renal resistive index as a novel biomarker for cardiovascular and kidney risk reduction in type II diabetes. <i>Journal of Clinical Hypertension</i> , 2020, 22, 231-233.	1.0	3
196	Outcomes of Carotid Revascularization in Patients With Chronic Kidney Disease. <i>Advances in Chronic Kidney Disease</i> , 2008, 15, 347-354.	0.6	2
197	Dual renin-angiotensin system blockade in the ONTARGET study: Clinically relevant risk for the kidney?. <i>Current Hypertension Reports</i> , 2009, 11, 375-381.	1.5	2
198	Metabolic Control of Blood Pressure Variability in Humans. <i>Journal of Clinical Hypertension</i> , 2016, 18, 25-26.	1.0	2

#	ARTICLE	IF	CITATIONS
199	Meal Frequency Differentially Alters Postprandial Triacylglycerol and Insulin Concentrations in Obese Women. <i>Obesity</i> , 0, , .	1.5	2
200	Obesity and chronic kidney disease: therapeutic implications. <i>Therapy: Open Access in Clinical Medicine</i> , 2007, 4, 585-595.	0.2	1
201	Aspirin and prevention of diabetes still a topic of debate. <i>Nature Reviews Endocrinology</i> , 2009, 5, 365-366.	4.3	1
202	Glycemic control and cardiovascular disease in a high-risk chronic kidney disease population. <i>Therapy: Open Access in Clinical Medicine</i> , 2009, 6, 507-513.	0.2	1
203	Renin-Angiotensin-Aldosterone System Inhibition and Improvement in Glucose Tolerance. <i>Journal of Clinical Hypertension</i> , 2009, 11, .	1.0	1
204	Is it Time to Target Prehypertension. <i>Cardiovascular Therapeutics</i> , 2010, 28, 337-338.	1.1	1
205	Biomarkers in diabetic kidney disease. <i>Therapy: Open Access in Clinical Medicine</i> , 2011, 8, 121-127.	0.2	1
206	CARDIOVASCULAR RISK MODIFICATION IN PARTICIPANTS WITH CORONARY DISEASE SCREENED BY THE KIDNEY EARLY EVALUATION PROGRAM. <i>Internal Medicine Journal</i> , 2010, , .	0.5	1
207	Exercise And The Metabolic Syndrome With Weight Regain. <i>Medicine and Science in Sports and Exercise</i> , 2009, 41, 523.	0.2	1
208	The cardiometabolic syndrome and chronic kidney disease. <i>Current Cardiovascular Risk Reports</i> , 2008, 2, 95-100.	0.8	0
209	Micro vs. Macrovascular Reactivity in Insulin Resistance: The Debate Reignited. <i>American Journal of Hypertension</i> , 2010, 23, 458-458.	1.0	0
210	Should Targeting Albuminuria Be Part of a Cardiovascular Risk Reduction Paradigm?. <i>Cardiology Clinics</i> , 2010, 28, 437-445.	0.9	0
211	Ask the Experts: How can the National Kidney Foundation's Kidney Early Evaluation Program help to prevent/manage kidney disease in diabetic patients?. <i>Diabetes Management</i> , 2011, 1, 365-368.	0.5	0
212	Initial Choice of Antihypertensive on Long-Term Cardiovascular Outcomes in CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 884-886.	2.2	0
213	The kaliuretic impact of cicletanine compared to hydrochlorothiazide. <i>Journal of Hypertension</i> , 2012, 30, 691-692.	0.3	0
214	Hypertension in Chronic Kidney Disease. , 2012, , 35-50.		0
215	Predictors of Kidney Disease in Diabetic, Hypertensive Patients. , 2012, , 107-119.		0
216	Diabetic Vascular Disease. , 2012, , 1321-1328.		0

#	ARTICLE	IF	CITATIONS
217	The Role of Insulin Resistance in the Cardiorenal Syndrome. , 2012, , 137-144.		0
218	Hypertension and Diabetes Mellitus. , 2013, , 313-319.		0
219	Novel interventions for resistant hypertension. Current Opinion in Nephrology and Hypertension, 2013, 22, 503.	1.0	0
220	Metabolic Impact of Adding a Thiazide Diuretic to Captopril. Hypertension, 2013, 61, 765-766.	1.3	0
221	Novel therapeutics in hypertension and kidney disease. Current Opinion in Nephrology and Hypertension, 2015, 24, 401-402.	1.0	0
222	Cardiorenal Metabolic Syndrome and Diabetes in African Americans: Adding to the Risk of Hypertension. , 2015, , 137-150.		0
223	Secondary Hypertension: Beginnings and Transitions. Advances in Chronic Kidney Disease, 2015, 22, 177-178.	0.6	0
224	BP Targets in Older Adults with CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1501-1503.	2.2	0
225	The Role of Insulin Resistance in the Cardiorenal Syndrome. , 2018, , 117-124.		0
226	Insulin Resistance and the Metabolic Syndrome in Kidney Disease (e.g., the Cardiorenal Metabolic) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50		
227	Overexpression of the Tissue Renin-Angiotensin System Causes Pulmonary Hypertension (PH) in TG(mRen2)27 Rat. FASEB Journal, 2007, 21, A1252.	0.2	0
228	Mineralocorticoid Receptor (MR) Inhibition Attenuates High Salt-Aldosterone Induced Increases in Vascular Renin-Angiotensin-Aldosterone System (RAAS) and Oxidative Stress. FASEB Journal, 2009, 23, 626.18.	0.2	0
229	Direct renin inhibition with Aliskiren lowers blood pressure and improves renal dysfunction in Ren2 rats. FASEB Journal, 2009, 23, 606.13.	0.2	0
230	Rosuvastatin Attenuates Pulmonary Arterial Hypertension in the Transgenic (mREN2)27 (Ren2) Rat. FASEB Journal, 2009, 23, 770.4.	0.2	0
231	Mineralocorticoid Receptor (MR) Antagonism Attenuates Glomerular Filtration Barrier Remodeling in the Transgenic Ren2 Rat. FASEB Journal, 2009, 23, 803.16.	0.2	0
232	Current Therapy Targeting Oxidative Stress: Statin. , 2011, , 351-366.		0
233	Effect of Age in RAS Activation and Insulin Signaling in the Pancreatic Tissue of db/db Mice. FASEB Journal, 2011, 25, 1063.7.	0.2	0
234	Cytokines in Skeletal Muscle Insulin Resistance. , 2011, , 369-383.		0

#	ARTICLE	IF	CITATIONS
235	Enhanced coronary vasoconstriction in western diet-induced obesity is associated with alterations in NHE1, SERCA2a and 3. FASEB Journal, 2013, 27, 1b660.	0.2	0
236	Chronic Kidney Disease and Cardiovascular Risk. Oxidative Stress in Applied Basic Research and Clinical Practice, 2014, , 49-61.	0.4	0
237	SAT-LB011 Role of Endothelium Epithelial Sodium Channel in Arterial Stiffness. Journal of the Endocrine Society, 2019, 3, .	0.1	0
238	Endothelial sodium channel (EnNaC) activation contributes to mineralocorticoid receptor-mediated increases in coronary artery and cardiac fibrosis/stiffness leading to diastolic dysfunction in obesity. FASEB Journal, 2020, 34, 1-1.	0.2	0